113 results
Search Results
2. Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience.
3. Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply.
4. Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply.
5. Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis.
6. Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions.
7. Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Authors' reply.
8. Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia?
9. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply.
10. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?
11. Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply.
12. Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug. Authors' reply.
13. Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug.
14. Corrigendum.
15. Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails—Authors' reply.
16. Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
17. Editorial: Is vedolizumab the preferred biologic therapy for biologic‐naïve patients with ulcerative colitis?
18. Editorial: LAG‐3‐depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
19. Editorial: Predicting paediatric ulcerative colitis outcomes—how can we improve?
20. Editorial: faecal incontinence in ulcerative colitis.
21. Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease.
22. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.
23. Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis—Authors' reply.
24. Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
25. Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring—author's reply.
26. Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
27. Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors' reply.
28. Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients.
29. Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
30. Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply.
31. Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure?
32. Editorial: treat‐to‐target in ulcerative colitis clinical management—a small price to pay? Authors' reply.
33. Editorial: treat‐to‐target in ulcerative colitis clinical management—a small price to pay?
34. Editorial: routine use of intestinal ultrasound in ulcerative colitis—are we missing the appendix? Authors' reply.
35. Editorial: routine use of intestinal ultrasound in ulcerative colitis—are we missing the appendix?
36. Editorial: selecting therapy for ulcerative colitis—think a step ahead.
37. Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study.
38. Letter: Chinese herbal medicine Curcumin–QingDai (CurQD)—A good treatment option for active ulcerative colitis? Authors' reply.
39. Letter: Chinese herbal medicine Curcumin‐QingDai (CurQD) – A good treatment option for active ulcerative colitis?
40. Letter: comedication use and dementia risk in patients with inflammatory bowel disease—authors' reply.
41. Editorial: histologic normalisation in ulcerative colitis.
42. Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis—Author's reply.
43. Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis.
44. Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?
45. Editorial: is older‐onset ulcerative colitis more severe or less aggressively managed? Authorsʼ reply.
46. Editorial: is older‐onset ulcerative colitis more severe or less aggressively managed?
47. Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis—an accurate early predictor of response to treatment. Authors' reply.
48. Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis—an accurate early predictor of response to treatment.
49. Letter: long‐term treatment of severe bile acid diarrhoea—obeticholic acid can normalise SeHCAT retention.
50. Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.